Influenza Virus A Antibodies, IgG and IgM (Separate Determinations), Serum
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Determination of recent infection when isolation of the organism by culture is unsuccessful
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
Influenza Virus A Ab, IgG, IgM, S
Specimen Type Describes the specimen type needed for testing
Specimen Required Defines the optimal specimen. This field describes the type of specimen required to perform the test and the preferred volume to complete testing. The volume allows automated processing, fastest throughput and, when indicated, repeat or reflex testing.
Preferred: Red top
Acceptable: Serum gel
Specimen Volume: 0.25 mL
1. Incidence of influenza virus infections is seasonal in the United States and usually occurs only from November to March.
2. Indicate influenza virus A.
Specimen Minimum Volume Defines the amount of specimen required to perform an assay once, including instrument and container dead space. Submitting the minimum specimen volume makes it impossible to repeat the test or perform confirmatory or perform reflex testing. In some situations, a minimum specimen volume may result in a QNS (quantity not sufficient) result, requiring a second specimen to be collected.
Mild OK; Gross reject
Mild OK; Gross reject
Specimen Stability Information Provides a description of the temperatures required to transport a specimen to the laboratory. Alternate acceptable temperature(s) are also included.
|Serum||Refrigerated (preferred)||14 days|
Clinical Information Discusses physiology, pathophysiology, and general clinical aspects, as they relate to a laboratory test
Influenza is usually a mild illness of the upper respiratory tract. Involvement of the lower respiratory tract, however, can lead to 4 types of clinical syndromes; physical signs of lower respiratory tract involvement without roentgenographic evidence of pneumonia, influenza complicated by bacterial pneumonia, primary influenza virus pneumonia, and combined influenzal and bacterial pneumonias.
Influenza virus infections are most severe in patients with certain preexisting conditions such as rheumatic heart disease, bronchopulmonary disease, impaired renal function, and diabetes mellitus. Infections can be more severe in elderly patients, pregnant females, and immunocompromised patients.
Influenza virus type A can produce serious illness during the first 2 years of life, with croup, bronchitis, and pneumonia being prominent.
Influenza A may also precipitate asthmatic attacks and produce chronic pulmonary complications in children.
Reference Values Describes reference intervals and additional information for interpretation of test results. May include intervals based on age and sex when appropriate. Intervals are Mayo-derived, unless otherwise designated. If an interpretive report is provided, the reference value field will state this.
The presence of IgM class antibodies or a 4-fold or greater rise in paired sera IgG titer indicates recent infection. The presence of demonstrable IgG generally indicates past exposure.
The presence of IgM class antibody or a 4-fold or greater rise in titer in paired (acute and convalescent) sera indicates recent infection.
The presence of IgG class antibody generally indicates past exposure.
Cautions Discusses conditions that may cause diagnostic confusion, including improper specimen collection and handling, inappropriate test selection, and interfering substances
Influenza virus infections occur exclusively from November through March.
Clinical Reference Provides recommendations for further in-depth reading of a clinical nature
1. Rothbarth PH, Groen J, Bohnen AM, et al: Influenza virus serology-a comparatvie study. J Virol Methods 1999;78:163-169
2. Pachucki CT: The diagnosis of influenza. Semin Resp Infect 1992;7:46-53
3. Wendt CH: Community respiratory viruses: organ transplant recipients. Am J Med 1997;102:31-36
Method Description Describes how the test is performed and provides a method-specific reference
Serum from the patient is diluted and placed in wells of substrate slides containing influenza virus-infected cells. A fluorescent antibody conjugate is then allowed to react with the virus-infected cells. (Smith TF: Unpublished Mayo information)
Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.
Monday through Friday; 9 a.m.
Analytic Time Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.
Maximum Laboratory Time Defines the maximum time from specimen receipt at Mayo Medical Laboratories until the release of the test result
Specimen Retention Time Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded
Performing Laboratory Location The location of the laboratory that performs the test
Test Classification Provides information regarding the medical device classification for laboratory test kits and reagents. Tests may be classified as cleared or approved by the US Food and Drug Administration (FDA) and used per manufacturer's instructions, or as products that do not undergo full FDA review and approval, and are then labeled as an Analyte Specific Reagent (ASR), Investigation Use Only (IUO) product, or a Research Use Only (RUO) product.
This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.
CPT Code Information Provides guidance in determining the appropriate Current Procedural Terminology (CPT) code(s) information for each test or profile. The listed CPT codes reflect Mayo Medical Laboratories interpretation of CPT coding requirements. It is the responsibility of each laboratory to determine correct CPT codes to use for billing.
86710 x 2
LOINC® Code Information Provides guidance in determining the Logical Observation Identifiers Names and Codes (LOINC) values for the result codes returned for this test or profile.
|Result ID||Reporting Name||LOINC Code|
|5731||Influenza Virus A Ab, IgG||43837-4|
|5732||Influenza Virus A Ab, IgM||43838-2|